The Recall Desk
ModerateFDA (Drugs)·D-0300-2026·Announced 2026-02-04

Glycopyrrolate oral solution recalled after failing impurity and degradation specifications

Novadoz Pharmaceuticals is recalling three lots of Glycopyrrolate Oral Solution, 1 mg/5 mL, after they failed impurities and degradation specifications.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: Scored 2 under the rule that FDA Class III actions fall at 1 or 2: the record cites failed impurity and degradation specifications with no stated clinical consequence.

Plain-English summary

Glycopyrrolate Oral Solution, 1 mg/5 mL, 16 oz (473 mL), Rx only, manufactured by MSN Pharmaceuticals Inc. of Piscataway, New Jersey and distributed by Novadoz Pharmaceuticals LLC, under NDC 72205-070-72, is being recalled.

The reason given in the enforcement record is failed impurities and degradation specifications.

The record's quantity field reads 'N/A'. The recall covers lots CB2505159A and CB2505160A, expiry 04/2027, and lot CB2505161A, expiry 05/2027. Distribution was nationwide in the US. The FDA has classified the action as Class III, its least serious category.

Patients should not stop taking a prescribed medicine without speaking to their prescriber or pharmacist, who can confirm whether a specific bottle is affected and arrange a replacement.

The recalled product

Product
GLYCOPYRROLATE (GLYCOPYRROLATE)
Brand
GLYCOPYRROLATE
Manufacturer
NOVADOZ PHARMACEUTICALS LLC
Hazard
  • impurity
  • degradation
  • out-of-specification
  • class-iii

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (5)

  • Lot # CB2505159A
  • CB2505160A
  • Exp Date: 04/2027
  • Lot # CB2505161A
  • Exp Date: 05/2027

Distribution

Distributed nationwide across the United States.